Bill Requiring White House to Provide Sequestration Specifics Moves Forward
Client Alert | less than 1 min read | 07.27.12
Following bipartisan passage (414-2) in the House on July 18, the Senate on Wednesday passed the Sequestration Transparency Act of 2012 requiring OMB to prepare a report for Congress within 30 days identifying each account to be sequestered and the resulting reductions at the program, project, and activity level; itemizing all exempt accounts; and providing any other data and explanations necessary to enhance public understanding of the sequester. While the Administration initially opposed the Act, press reports now indicate that the President will likely sign the bill into law.
Contacts
Insights
Client Alert | 9 min read | 10.21.26
The life sciences sector is uniquely vulnerable to the inherent risks of AI-generated evidence in drug development and discovery. This client alert focuses on five core challenges: hallucinations, skewed predictions from unrepresentative training data, the opacity of AI reasoning, input sensitivity that undermines reproducibility, and adversarial manipulation of training data. To address these risks, companies should use experimental validation and human oversight as the common legal and regulatory safety net. This entails among other measures auditing AI outputs, characterizing training data, and structural oversight. Companies also should prepare for evolving frameworks and guidance from the U.S. Food and Drug Administration (FDA) and the European Union (EU) that address use of AI in drug discovery and development .
Client Alert | 2 min read | 10.21.26
Client Alert | 3 min read | 10.21.26
Private Investigations Act Series: Temporal, material and territorial scope
Client Alert | 7 min read | 10.21.26
